spacer
home > ebr > autumn 2017 > homing in
PUBLICATIONS
European Biopharmaceutical Review

Homing In

Since the first daVinci surgical systems began marketing in 1999 and the following acquisition of Computer Motion by Intuitive Surgical in 2003, very few innovations have been made in the field. Initial adoption of such technology was limited and most surgeons were highly sceptical about its future. However, over the span of 15 years, Intuitive Surgical transformed robotic surgery from an interesting market experiment to an established technique. Today, analysts project exponential growth in the years to come, and nobody doubts that the future is in robotics.

As initial patents expire and new technologies are developed, a rising number of modern robotic surgical systems have been, or are about to be, launched. The competition for shares will be fierce.

Perfecting Platforms

The market might seem big enough for everybody, but the reality could be more complex. For most hospitals, adopting a given robotic surgical platform is a big decision and is not easily reversible, as it involves significant costs and efforts, such as staff training. Due to the requirements for an increased number of operating rooms and storage, a costly multi-platform-adapted staff and a complex maintenance organisation, working with two different types of robotic platforms is also unlikely. However, bigger hospitals that might actually need to utilise several robotic platforms could reduce costs by taking advantage of economies of scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Andre Faure has a surgical background and decided to interrupt his early medical career to develop new surgical devices. For more than 15 years, he has led several multi-national R&D programmes in the field where he has developed robotic surgical instruments, including devices for treating atrial fibrillation and liver cancer. Andre is also the founder of Trod Medical, a company created around one of his inventions – a robotic device specifically developed for localised prostate cancer treatment.
spacer
Dr Andre Faure
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

 
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement